Chugai Pharmaceutical Co., Ltd. announced that it filed regulatory applications with the Ministry of Health, Labour and Welfare for the anti-C5 antibody crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) on June 14, 2023.
Found this useful? Share it with your team.
